$323 Million is the total value of venBio Partners LLC's 7 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 12.5% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Sell | VENTYX BIOSCIENCES INC | $113,503,765 | -35.1% | 3,461,536 | -30.9% | 35.19% | -13.1% | |
ALXO | ALX ONCOLOGY HLDGS INC | $109,318,155 | +17.8% | 9,699,925 | 0.0% | 33.89% | +57.8% | |
HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $57,050,320 | +14.4% | 1,035,396 | -8.0% | 17.69% | +53.3% |
PHVS | PHARVARIS N V | $25,837,988 | +46.7% | 2,296,710 | 0.0% | 8.01% | +96.5% | |
IMPL | IMPEL PHARMACEUTICALS INC | $10,349,216 | -23.0% | 2,759,791 | 0.0% | 3.21% | +3.2% | |
Sell | CINCOR PHARMA INC | $4,711,863 | -92.3% | 383,390 | -79.4% | 1.46% | -89.7% | |
ELEV | ELEVATION ONCOLOGY INC | $1,773,022 | -15.9% | 1,866,339 | 0.0% | 0.55% | +12.7% | |
AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -596,483 | -100.0% | -4.70% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
VERONA PHARMA PLC | 15 | Q2 2022 | 22.2% |
AKERO THERAPEUTICS INC | 14 | Q3 2022 | 65.3% |
ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 73.8% |
HARMONY BIOSCIENCES HLDGS IN | 13 | Q3 2023 | 21.1% |
APELLIS PHARMACEUTICALS INC | 11 | Q2 2021 | 62.0% |
PHARVARIS N V | 11 | Q3 2023 | 25.2% |
IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.3% |
ELEVATION ONCOLOGY INC | 10 | Q3 2023 | 4.2% |
VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 42.7% |
PRECISION BIOSCIENCES INC | 7 | Q3 2020 | 62.0% |
View venBio Partners LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-15 |
View venBio Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.